Appropriate and inappropriate use of immunotherapy (Q34321339)

1 August 2017

1 reference

title

Appropriate and inappropriate use of immunotherapy (English)

1 reference

1 August 2017

1 reference

DuBuske LM

1

1 reference

1 August 2017

publication date

1 July 2001

1 reference

Annals of Allergy, Asthma & Immunology

1 August 2017

published in

1 reference

1 August 2017

volume

87

1 reference

1 August 2017

issue

1 Suppl 1

1 reference

1 August 2017

page(s)

56-67

1 reference

Immunotherapy in asthma: an updated systematic review

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962196-5

7 January 2021

Allergen immunotherapy: therapeutic vaccines for allergic diseases. Geneva: January 27-29 1997

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962196-5

7 January 2021

A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962196-5

7 January 2021

A comparative study of the effectiveness of the Rinkel method and the current standard method of immunotherapy for ragweed pollen hay fever

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962196-5

7 January 2021

Treatment of peanut allergy with rush immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962196-5

7 January 2021

Clinical and immunological effects of oral immunotherapy with a standardized birch pollen extract

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962196-5

7 January 2021

A double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962196-5

7 January 2021

Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962196-5

7 January 2021

Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962196-5

7 January 2021

Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962196-5

7 January 2021

Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962196-5

7 January 2021

Local immunotherapy: pharmacokinetics and efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962196-5

7 January 2021

Sublingual immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962196-5

7 January 2021

Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962196-5

7 January 2021

Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: A double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962196-5

7 January 2021

Sublingual immunotherapy: a double-blind, placebo-controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma, or both.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962196-5

7 January 2021

Post-marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962196-5

7 January 2021

The Present State of our Knowledge of Hay-Fever: Being a Paper Presented at the Berlin Congress of the Royal Institute of Public Health

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962196-5

7 January 2021

Detection of IgE-binding activity in serum after intranasal treatment of normal rabbits with P. judaica extract

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962196-5

7 January 2021

Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962196-5

7 January 2021

Nasal immunotherapy to Parietaria: evidence of reduction of local allergic inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962196-5

7 January 2021

Local nasal immunotherapy with extract in powder form is effective and safe in grass pollen rhinitis: a double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962196-5

7 January 2021

A double-blind, placebo-controlled trial of local nasal immunotherapy in allergic rhinitis to Parietaria pollen

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962196-5

7 January 2021

Local nasal immunotherapy for birch allergic rhinitis with extract in powder form

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962196-5

7 January 2021

Local nasal immunotherapy in allergic rhinitis to Parietaria. A double-blind controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962196-5

7 January 2021

Local nasal immunotherapy for Dermatophagoides-induced rhinitis: efficacy of a powder extract

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962196-5

7 January 2021

Food allergy and the role of immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962196-5

7 January 2021

A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962196-5

7 January 2021

10.1016/S1081-1206(10)62196-5

Identifiers

DOI

1 reference

1 August 2017

1 reference